Sri LankaTuberculosis profile
Population  2014 21 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (1–1.6) 6.1 (4.8–7.6)
Mortality (HIV+TB only) 0.014 (0.01–0.018) 0.07 (0.05–0.09)
Prevalence  (includes HIV+TB) 20 (10–34) 99 (51–164)
Incidence  (includes HIV+TB) 13 (12–15) 65 (57–73)
Incidence (HIV+TB only) 0.053 (0.041–0.066) 0.26 (0.2–0.32)
         
Case detection, all forms (%) 69 (62–79)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.18 (0–0.99) 0.58 (0.07–2.1)
MDR-TB cases among notified pulmonary
TB cases
11 (0–62) 3 (0–10)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 4 345   288
Pulmonary, clinically diagnosed 1 962   0
Extrapulmonary 2 710   0
       
Total new and relapse 9 305    
Previously treated, excluding relapses 168    
Total cases notified 9 473    
Among 8 980 new and relapse cases:
313 (3%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 209 (28%) 669 (147%) 1 816
Laboratory-confirmed RR-/MDR-TB cases     42
Patients started on MDR-TB treatment ***     11
TB/HIV 2014 Number (%)
TB patients with known HIV status 7 418 (78)
HIV-positive TB patients 21 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 18 (86)
HIV-positive TB patients on antiretroviral therapy (ART) 18 (86)
HIV-positive people screened for TB 245  
HIV-positive people provided with IPT 9  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (85) 9 010
Previously treated cases, excluding relapse, registered in 2013 (62) 167
HIV-positive TB cases, all types, registered in 2013 (24) 37
RR-/MDR-TB cases started on second-line treatment in 2012 (88) 8
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 17
% Funded domestically 73%
% Funded internationally 21%
% Unfunded 6%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-28 Data: www.who.int/tb/data